Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Emergency Service, Hospital | 15 | 2023 | 221 | 3.090 |
Why?
|
| Ultrasonography | 13 | 2023 | 226 | 2.540 |
Why?
|
| Point-of-Care Systems | 5 | 2023 | 53 | 2.190 |
Why?
|
| Abscess | 4 | 2020 | 26 | 2.140 |
Why?
|
| Soft Tissue Infections | 3 | 2020 | 28 | 1.940 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2020 | 19 | 1.420 |
Why?
|
| Heart Arrest | 2 | 2020 | 58 | 1.360 |
Why?
|
| Shoulder Dislocation | 2 | 2022 | 94 | 1.340 |
Why?
|
| Anti-Bacterial Agents | 6 | 2021 | 402 | 1.340 |
Why?
|
| Humans | 50 | 2023 | 29361 | 1.270 |
Why?
|
| Warfarin | 3 | 2022 | 37 | 1.100 |
Why?
|
| Trachea | 3 | 2022 | 31 | 1.060 |
Why?
|
| Hyperkalemia | 2 | 2021 | 7 | 0.960 |
Why?
|
| Blood Coagulation Factors | 3 | 2022 | 18 | 0.960 |
Why?
|
| Acute Kidney Injury | 2 | 2021 | 49 | 0.950 |
Why?
|
| Drainage | 3 | 2020 | 50 | 0.950 |
Why?
|
| Fractures, Bone | 2 | 2022 | 75 | 0.940 |
Why?
|
| Retrospective Studies | 18 | 2023 | 3273 | 0.930 |
Why?
|
| Esophagus | 3 | 2022 | 59 | 0.930 |
Why?
|
| Ventricular Fibrillation | 2 | 2020 | 30 | 0.900 |
Why?
|
| Hemorrhage | 2 | 2020 | 75 | 0.880 |
Why?
|
| Antiemetics | 1 | 2022 | 8 | 0.850 |
Why?
|
| Intubation, Intratracheal | 3 | 2022 | 77 | 0.850 |
Why?
|
| Hypoglycemia | 2 | 2021 | 14 | 0.840 |
Why?
|
| Sympathomimetics | 1 | 2021 | 8 | 0.830 |
Why?
|
| Emergency Medicine | 2 | 2020 | 79 | 0.820 |
Why?
|
| Pharmacy Service, Hospital | 2 | 2020 | 9 | 0.820 |
Why?
|
| Airway Management | 1 | 2021 | 16 | 0.820 |
Why?
|
| Critical Illness | 3 | 2021 | 123 | 0.820 |
Why?
|
| Ketamine | 1 | 2021 | 33 | 0.800 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 42 | 0.790 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 56 | 0.780 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 85 | 0.760 |
Why?
|
| Allied Health Personnel | 1 | 2020 | 12 | 0.760 |
Why?
|
| Efficiency, Organizational | 1 | 2020 | 15 | 0.760 |
Why?
|
| Bites and Stings | 1 | 2020 | 4 | 0.760 |
Why?
|
| Phenytoin | 1 | 2020 | 16 | 0.760 |
Why?
|
| Skin Diseases | 1 | 2020 | 26 | 0.750 |
Why?
|
| Inappropriate Prescribing | 1 | 2020 | 6 | 0.750 |
Why?
|
| Documentation | 1 | 2020 | 31 | 0.750 |
Why?
|
| Wound Infection | 1 | 2020 | 13 | 0.750 |
Why?
|
| Status Epilepticus | 1 | 2020 | 48 | 0.730 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 34 | 0.720 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 42 | 0.710 |
Why?
|
| Anticonvulsants | 1 | 2020 | 109 | 0.710 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 97 | 0.700 |
Why?
|
| Gonorrhea | 1 | 2019 | 8 | 0.700 |
Why?
|
| Chlamydia Infections | 1 | 2019 | 8 | 0.700 |
Why?
|
| Glucagon | 1 | 2019 | 4 | 0.690 |
Why?
|
| Aftercare | 1 | 2019 | 22 | 0.690 |
Why?
|
| Gastrointestinal Agents | 1 | 2019 | 12 | 0.690 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 148 | 0.690 |
Why?
|
| Retinal Detachment | 1 | 2019 | 6 | 0.690 |
Why?
|
| Pulmonary Edema | 3 | 2023 | 19 | 0.690 |
Why?
|
| Adult | 14 | 2023 | 8604 | 0.680 |
Why?
|
| Foreign Bodies | 1 | 2019 | 25 | 0.670 |
Why?
|
| Epistaxis | 1 | 2018 | 9 | 0.670 |
Why?
|
| Spinal Puncture | 1 | 2018 | 27 | 0.660 |
Why?
|
| Antifibrinolytic Agents | 1 | 2018 | 23 | 0.660 |
Why?
|
| Male | 18 | 2023 | 15637 | 0.650 |
Why?
|
| Tranexamic Acid | 1 | 2018 | 23 | 0.650 |
Why?
|
| Skin Diseases, Infectious | 1 | 2018 | 9 | 0.640 |
Why?
|
| Anthrax | 1 | 2017 | 1 | 0.630 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2017 | 2 | 0.630 |
Why?
|
| Transportation of Patients | 1 | 2017 | 6 | 0.630 |
Why?
|
| Mass Casualty Incidents | 1 | 2017 | 7 | 0.630 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 63 | 0.630 |
Why?
|
| Health Resources | 1 | 2017 | 24 | 0.620 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 36 | 0.610 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 35 | 0.610 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 295 | 0.610 |
Why?
|
| Female | 17 | 2023 | 16211 | 0.590 |
Why?
|
| Anticoagulants | 3 | 2022 | 100 | 0.540 |
Why?
|
| Middle Aged | 13 | 2023 | 9823 | 0.510 |
Why?
|
| Azoles | 1 | 2014 | 1 | 0.500 |
Why?
|
| Tacrolimus | 1 | 2014 | 12 | 0.500 |
Why?
|
| Sirolimus | 1 | 2014 | 15 | 0.490 |
Why?
|
| Antifungal Agents | 1 | 2014 | 36 | 0.490 |
Why?
|
| Treatment Failure | 3 | 2020 | 159 | 0.490 |
Why?
|
| Sensitivity and Specificity | 6 | 2023 | 553 | 0.480 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 132 | 0.460 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 91 | 0.460 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 340 | 0.450 |
Why?
|
| Atrial Fibrillation | 3 | 2020 | 183 | 0.420 |
Why?
|
| Algorithms | 1 | 2014 | 400 | 0.410 |
Why?
|
| Pneumonia, Staphylococcal | 2 | 2021 | 9 | 0.400 |
Why?
|
| Metoprolol | 3 | 2020 | 8 | 0.400 |
Why?
|
| Diltiazem | 3 | 2020 | 6 | 0.400 |
Why?
|
| Treatment Outcome | 5 | 2020 | 3476 | 0.400 |
Why?
|
| Prospective Studies | 5 | 2023 | 1812 | 0.390 |
Why?
|
| Pharmacists | 2 | 2021 | 16 | 0.390 |
Why?
|
| Intestinal Obstruction | 2 | 2023 | 12 | 0.380 |
Why?
|
| Intensive Care Units | 3 | 2021 | 301 | 0.350 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2021 | 124 | 0.340 |
Why?
|
| Insulin | 2 | 2021 | 92 | 0.340 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2020 | 104 | 0.330 |
Why?
|
| International Normalized Ratio | 3 | 2022 | 23 | 0.280 |
Why?
|
| Aged | 8 | 2021 | 9447 | 0.280 |
Why?
|
| Vomiting | 2 | 2023 | 18 | 0.280 |
Why?
|
| Nausea | 2 | 2023 | 27 | 0.270 |
Why?
|
| Chicago | 2 | 2019 | 865 | 0.270 |
Why?
|
| Heart Failure | 2 | 2018 | 204 | 0.260 |
Why?
|
| Point-of-Care Testing | 2 | 2023 | 24 | 0.260 |
Why?
|
| Child | 2 | 2020 | 1345 | 0.260 |
Why?
|
| Nasal Cavity | 2 | 2021 | 35 | 0.240 |
Why?
|
| Nystagmus, Pathologic | 1 | 2023 | 3 | 0.240 |
Why?
|
| Potassium | 2 | 2021 | 67 | 0.240 |
Why?
|
| Dizziness | 1 | 2023 | 20 | 0.240 |
Why?
|
| Vancomycin | 2 | 2021 | 57 | 0.230 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 241 | 0.230 |
Why?
|
| Blood Glucose | 2 | 2021 | 112 | 0.220 |
Why?
|
| Eye | 1 | 2022 | 10 | 0.220 |
Why?
|
| Metoclopramide | 1 | 2022 | 3 | 0.220 |
Why?
|
| Thrombosis | 2 | 2020 | 59 | 0.210 |
Why?
|
| Cystitis | 1 | 2021 | 11 | 0.200 |
Why?
|
| Neuroimaging | 1 | 2022 | 136 | 0.200 |
Why?
|
| Stroke Volume | 2 | 2018 | 56 | 0.200 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 32 | 0.200 |
Why?
|
| Urinary Tract Infections | 1 | 2021 | 32 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 333 | 0.200 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 17 | 0.190 |
Why?
|
| Publications | 1 | 2020 | 14 | 0.190 |
Why?
|
| Hypercalcemia | 1 | 2020 | 12 | 0.190 |
Why?
|
| Calcitonin | 1 | 2020 | 15 | 0.190 |
Why?
|
| Piracetam | 1 | 2020 | 14 | 0.190 |
Why?
|
| Cardiovascular Agents | 1 | 2020 | 28 | 0.190 |
Why?
|
| Job Satisfaction | 1 | 2020 | 28 | 0.190 |
Why?
|
| Diphosphonates | 1 | 2020 | 17 | 0.190 |
Why?
|
| Blood Coagulation | 1 | 2020 | 21 | 0.190 |
Why?
|
| Benzodiazepines | 1 | 2020 | 60 | 0.190 |
Why?
|
| Publishing | 1 | 2020 | 38 | 0.190 |
Why?
|
| Cellulitis | 1 | 2020 | 8 | 0.180 |
Why?
|
| Dogs | 1 | 2020 | 253 | 0.180 |
Why?
|
| Young Adult | 2 | 2017 | 1935 | 0.180 |
Why?
|
| Seizures | 1 | 2020 | 87 | 0.180 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2019 | 7 | 0.180 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 215 | 0.180 |
Why?
|
| Chlamydia trachomatis | 1 | 2019 | 18 | 0.180 |
Why?
|
| Mass Screening | 1 | 2021 | 177 | 0.170 |
Why?
|
| Midodrine | 1 | 2019 | 4 | 0.170 |
Why?
|
| Bezoars | 1 | 2019 | 2 | 0.170 |
Why?
|
| Peristalsis | 1 | 2019 | 11 | 0.170 |
Why?
|
| Shock | 1 | 2019 | 9 | 0.170 |
Why?
|
| Physical Examination | 1 | 2020 | 117 | 0.170 |
Why?
|
| Blood Pressure | 1 | 2020 | 238 | 0.170 |
Why?
|
| Manipulation, Orthopedic | 1 | 2019 | 10 | 0.170 |
Why?
|
| Electronic Health Records | 1 | 2019 | 66 | 0.170 |
Why?
|
| Administration, Topical | 1 | 2018 | 17 | 0.170 |
Why?
|
| Staphylococcal Infections | 1 | 2021 | 176 | 0.170 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 150 | 0.170 |
Why?
|
| Capnography | 1 | 2018 | 9 | 0.170 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 389 | 0.170 |
Why?
|
| Sepsis | 1 | 2020 | 144 | 0.160 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 324 | 0.160 |
Why?
|
| Lung | 3 | 2023 | 154 | 0.160 |
Why?
|
| Bacillus anthracis | 1 | 2017 | 1 | 0.160 |
Why?
|
| Bioterrorism | 1 | 2017 | 6 | 0.160 |
Why?
|
| Ciprofloxacin | 1 | 2017 | 29 | 0.160 |
Why?
|
| Disaster Planning | 1 | 2017 | 10 | 0.160 |
Why?
|
| Renal Insufficiency | 1 | 2017 | 13 | 0.160 |
Why?
|
| Doxycycline | 1 | 2017 | 22 | 0.160 |
Why?
|
| Bandages | 1 | 2017 | 8 | 0.160 |
Why?
|
| Length of Stay | 1 | 2019 | 317 | 0.160 |
Why?
|
| Neoplasms | 1 | 2020 | 247 | 0.150 |
Why?
|
| Intestine, Small | 1 | 2017 | 33 | 0.150 |
Why?
|
| Odds Ratio | 1 | 2018 | 285 | 0.150 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 364 | 0.150 |
Why?
|
| Time Factors | 2 | 2021 | 1618 | 0.150 |
Why?
|
| Illinois | 1 | 2017 | 241 | 0.150 |
Why?
|
| Infant | 1 | 2018 | 531 | 0.140 |
Why?
|
| Pain Measurement | 1 | 2018 | 462 | 0.140 |
Why?
|
| Child, Preschool | 1 | 2018 | 641 | 0.140 |
Why?
|
| Voriconazole | 1 | 2014 | 8 | 0.130 |
Why?
|
| Fluconazole | 1 | 2014 | 7 | 0.130 |
Why?
|
| Drug Dosage Calculations | 1 | 2014 | 6 | 0.130 |
Why?
|
| Mycoses | 1 | 2014 | 22 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 17 | 0.120 |
Why?
|
| Triazoles | 1 | 2014 | 30 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2019 | 1939 | 0.120 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 75 | 0.100 |
Why?
|
| Adolescent | 1 | 2017 | 2280 | 0.100 |
Why?
|
| Animals | 1 | 2020 | 4577 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 788 | 0.100 |
Why?
|
| Professional Role | 2 | 2021 | 27 | 0.100 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 4851 | 0.090 |
Why?
|
| Administration, Intravenous | 2 | 2019 | 29 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 437 | 0.080 |
Why?
|
| Incidence | 2 | 2020 | 756 | 0.070 |
Why?
|
| Vertigo | 1 | 2023 | 8 | 0.060 |
Why?
|
| Pleura | 1 | 2023 | 9 | 0.060 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 22 | 0.060 |
Why?
|
| Glasgow Coma Scale | 1 | 2022 | 12 | 0.050 |
Why?
|
| Linezolid | 1 | 2021 | 6 | 0.050 |
Why?
|
| Cadaver | 1 | 2022 | 359 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2022 | 129 | 0.050 |
Why?
|
| Penicillanic Acid | 1 | 2020 | 3 | 0.050 |
Why?
|
| Piperacillin | 1 | 2020 | 3 | 0.050 |
Why?
|
| Medical Records | 1 | 2020 | 29 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2020 | 65 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2021 | 149 | 0.050 |
Why?
|
| Heart Rate | 1 | 2020 | 142 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2021 | 140 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2019 | 28 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 206 | 0.040 |
Why?
|
| Logistic Models | 1 | 2020 | 407 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 236 | 0.040 |
Why?
|
| Critical Care | 1 | 2021 | 234 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 317 | 0.040 |
Why?
|
| Acute Disease | 1 | 2018 | 226 | 0.040 |
Why?
|